New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma
Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory...
Saved in:
Main Authors: | M. А. Sorokina, A. V. Rakhteenko, T. R. Grishina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2023-07-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/807 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unspecified skin peripheral T-cell lymphoma: diagnostic difficulties
by: O. Yu. Olisova, et al.
Published: (2020-10-01) -
Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01) -
Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research)
by: E. I. Kankumasheva, et al.
Published: (2020-01-01) -
Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)